Therapeutic strategies for Gaucher disease: Miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase

Molecular Pharmaceutics

Volumn 8, Issue 6, 2011, Pages 2390-2397

  Abian, Olga ^a,b,c,d   Alfonso, Pilar ^a,b,e   Velazquez Campoy, Adrian ^c,f   Giraldo, Pilar ^a,b,e   Pocovi, Miguel ^b,c,e   Sancho, Javier ^c  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^f FUNDACIÓN ARAID   (Spain)

Author keywords

calorimetry; Gaucher disease; imiglucerase; NB DNJ; velaglucerase alfa

Indexed keywords

CHAPERONE; GLUCOSYLCERAMIDASE; IMIGLUCERASE; MIGLUSTAT; VELAGLUCERASE ALFA;

ARTICLE; DRUG BINDING; DRUG CONFORMATION; DRUG EFFECT; DRUG STABILITY; ENZYME ACTIVITY; GAUCHER DISEASE; PH; PRIORITY JOURNAL; THERMOSTABILITY;

1-DEOXYNOJIRIMYCIN; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG STABILITY; ENZYME STABILITY; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; TEMPERATURE;

EID: 82955173021     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200313e     Document Type: Article

References (65)

1. Brady, R. O.; Kanfer, J. N.; Shapiro, D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease Biochem. Biophys. Res. Commun. 1965, 18, 221-225
2. Beutler, E.; Grabowski, G. A. Gaucher disease. In The metabolic and molecular bases of inherited diseases, 8 th ed.; Scriver, C. R.; Beaudet, A. L.; Sly, W. S.; Valle, D., Eds.; McGraw-Hill: New York, 2001; pp 3635-3668.
3. Futerman, A. H.; Sussman, J. L.; Horowitz, M.; Silman, I.; Zimran, A. New directions in the treatment of Gaucher disease Trends Pharmacol. Sci. 2004, 25, 147-151 (Pubitemid 38264505)
4. Sawkar, A. R.; D'Haeze, W.; Kelly, J. W. Therapeutic strategies to ameliorate lysosomal storage disorders - a focus on Gaucher disease Cell. Mol. Life Sci. 2006, 63, 1179-1192 (Pubitemid 43939004)
5. Brady, R. O. Therapy for the sphingolipidoses Arch. Neurol. 1998, 55, 1055-1056 (Pubitemid 28367229)
6. Bijsterbosch, M. K.; Donker, W.; van de Bilt, H.; van Weely, S.; van Berkel, T. J.; Aerts, J. M. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells Eur. J. Biochem. 1996, 237, 344-349
7. Mistry, P. K.; Wraight, E. P.; Cox, T. M. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease Lancet 1996, 348, 1555-1559 (Pubitemid 26411655)
8. Zimran, A.; Loveday, K.; Fratazzi, C.; Elstein, D. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease Blood Cells, Mol., Dis. 2007, 39, 115-118 (Pubitemid 46754922)
9. Barton, N. W.; Brady, R. O.; Dambrosia, J. M.; Di Bisceglie, A. M.; Doppelt, S. H.; Hill, S. C. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease N. Engl. J. Med. 1991, 324, 1464-1470
10. Schiffmann, R.; Heyes, M. P.; Aerts, J. M.; Dambrosia, J. M.; Patterson, M. C.; DeGraba, T. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease Ann. Neurol. 1997, 2, 613-621 (Pubitemid 27439024)
11. Weinreb, N. J.; Charrow, J.; Andersson, H. C.; Kaplan, P.; Kolodny, E. H.; Mistry, P. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry Am. J. Med. 2002, 113, 112-119 (Pubitemid 34804747)
12. Brady, R. O. Enzyme replacement for lysosomal diseases Annu. Rev. Med. 2006, 57, 283-296 (Pubitemid 43261992)
13. Grabowski, G. A.; Leslie, N.; Wenstrup, R. Enzyme therapy for Gaucher disease: the first 5 years Blood Rev. 1998, 12, 115-133 (Pubitemid 28327418)
14. Weinreb, N. J.; Barranger, J. A.; Charrow, J.; Grabowski, G. A.; Mankin, H. J.; Mistry, P. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease Am. J. Hematol. 2005, 80, 223-229 (Pubitemid 41579546)
15. Beutler, E. Lysosomal storage diseases: natural history and ethical and economic aspects Mol. Genet. Metab. 2006, 88, 208-215 (Pubitemid 43963435)
16. Platt, F. M.; Jeyakumar, M.; Andersson, U.; Priestman, D. A.; Dwek, R. A.; Butters, T. D. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy J. Inherited Metab. Dis. 2001, 24, 275-290 (Pubitemid 32479421)
17. Lachmann, R. H. Miglustat. Oxford GlycoSciences/Actelion Curr. Opin. Invest. Drugs 2003, 4, 472-479
18. Cox, T.; Lachmann, R.; Hollak, C.; Aerts, J.; van Weely, S.; Hrebícek, M. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis Lancet 2000, 355, 1481-1485 (Pubitemid 30237353)
19. Elstein, D.; Hollak, C.; Aerts, J. M.; van Weely, S.; Maas, M.; Cox, T. M. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease J. Inherited Metab. Dis. 2004, 27, 757-766 (Pubitemid 39433603)
20. Giraldo, P.; Latre, P.; Alfonso, P.; Acedo, A.; Alonso, D.; Barez, A. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease Haematologica 2006, 91, 703-706 (Pubitemid 43799475)
21. Elstein, D.; Dweck, A.; Attias, D.; Hadas-Halpern, I.; Zevin, S.; Altarescu, G. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement Blood 2007, 110, 2296-2301 (Pubitemid 47523147)
22. Pastores, G. M.; Elstein, D.; Hrebícek, M.; Zimran, A. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies Clin. Ther. 2007, 29, 1645-1654 (Pubitemid 47494543)
23. Giraldo, P.; Alfonso, P.; Atutxa, K.; Fernández-Galán, M. A.; Barez, A.; Franco, R. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project Haematologica 2009, 94, 1771-1775
24. Fan, J. Q.; Ishii, S.; Asano, N.; Suzuki, Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor Nat. Med. 1999, 5, 112-115 (Pubitemid 29051008)
25. Ulloa-Aguirre, A.; Janovick, J. A.; Brothers, S. P.; Conn, P. M. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease Traffic 2004, 5, 821-837 (Pubitemid 39433553)
26. Arakawa, T.; Ejima, D.; Kita, Y.; Tsumoto, K. Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs Biochim. Biophys. Acta 2006, 1764, 1677-1687 (Pubitemid 46053854)
27. Leandro, P.; Gomes, C. M. Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning Mini-Rev. Med. Chem. 2008, 8, 901-11
28. Ellgaard, L.; Molinari, M.; Helenius, A. Setting the standards: quality control in the secretory pathway Science 1999, 286, 1882-1888 (Pubitemid 129515888)
29. Ellgaard, L.; Helenius, A. Quality control in the endoplasmic reticulum Nat. Rev. Mol. Cell Biol. 2003, 4, 181-191 (Pubitemid 36288040)
30. Sawkar, A. R.; Schmitz, M.; Zimmer, K. P.; Reczek, D.; Edmunds, T.; Balch, W. E. Clinical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants ACS Chem. Biol. 2006, 1, 235-251
31. Anderson, R. G.; Orci, L. A view of acidic intracellular compartments J. Cell Biol. 1988, 106, 539-543 (Pubitemid 18089954)
32. Sawkar, A. R.; Cheng, W. C.; Beutler, E.; Wong, C. H.; Balch, W. E.; Kelly, J. W. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 15428-15433 (Pubitemid 35403951)
33. Alfonso, P.; Pampín, S.; Estrada, J.; Rodríguez-Rey, J. C.; Giraldo, P.; Sancho, J. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations Blood Cells, Mol., Dis. 2005, 35, 268-276 (Pubitemid 41267059)
34. Sawkar, A. R.; Adamski-Werner, S. L.; Cheng, W. C.; Wong, C. H.; Beutler, E.; Zimmer, K. P. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles Chem. Biol. 2005, 12, 1235-1244 (Pubitemid 41628259)
35. Steet, R. A.; Chung, S.; Wustman, B.; Powe, A.; Do, H.; Kornfeld, S. A. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13813-13818 (Pubitemid 44413990)
36. Benjamin, E. R.; Flanagan, J. J.; Schilling, A.; Chang, H. H.; Agarwal, L.; Katz, E. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines J. Inherited Metab. Dis. 2009, 32, 424-440
37. Kato, A.; Yamashita, Y.; Nakagawa, S.; Koike, Y.; Adachi, I.; Hollinshead, J. 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease Bioorg. Med. Chem. 2010, 18, 3790-3794
38. Lieberman, R. L.; Wustman, B. A.; Huertas, P.; Powe, A. C., Jr.; Pine, C. W.; Khanna, R. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease Nat. Chem. Biol. 2007, 3, 101-107 (Pubitemid 46134996)
39. Kornhaber, G. J.; Tropak, M. B.; Maegawa, G. H.; Tuske, S. J.; Coales, S. J.; Mahuran, D. J. Isofagomine induced stabilization of glucocerebrosidase ChemBioChem 2008, 9, 2643-2649
40. Grabowski, G. A. Treatment perspectives for the lysosomal storage diseases Expert Opin. Emerging Drugs 2008, 13, 197-211 (Pubitemid 351448710)
41. Shen, J. S.; Edwards, N. J.; Hong, Y. B.; Murray, G. J. Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase Biochem. Biophys. Res. Commun. 2008, 369, 1071-1075
42. Horowitz, M.; Wilder, S.; Horowitz, Z.; Reiner, O.; Gelbart, T.; Beutler, E. The human glucocerebrosidase gene and pseudogene: structure and evolution Genomics 1989, 4, 87-96
43. Grabowski, G. A.; Gatt, S.; Horowitz, M. Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease Crit. Rev. Biochem. Mol. Biol. 1990, 25, 385-414 (Pubitemid 120012280)
44. Dvir, H.; Harel, M.; McCarthy, A. A.; Toker, L.; Silman, I.; Futerman, A. H. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease EMBO Rep. 2003, 4, 704-709 (Pubitemid 36974756)
45. Brumshtein, B.; Greenblatt, H. M.; Butters, T. D.; Shaaltiel, Y.; Aviezer, D.; Silman, I Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease J. Biol. Chem. 2007, 282, 29052-29058 (Pubitemid 47606022)
46. Brumshtein, B.; Salinas, P.; Peterson, B.; Chan, V.; Silman, I.; Sussman, J. L. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages Glycobiology 2010, 20, 24-32
47. Premkumar, L.; Sawkar, A. R.; Boldin-Adamsky, S.; Toker, L.; Silman, I.; Kelly, J. W. X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease J. Biol. Chem. 2005, 280, 23815-23819 (Pubitemid 40884867)
48. Xu, Y. H.; Ponce, E.; Sun, Y.; Leonova, T.; Bove, K.; Witte, D. Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues Pediatr. Res. 1996, 39, 313-322 (Pubitemid 26039557)
49. Grabowski, G. A. Delivery of lysosomal enzymes for therapeutic use: glucocerebrosidase as an example Expert Opin. Drug Delivery 2006, 3, 771-782 (Pubitemid 44781849)
50. Lieberman, R. L.; D́aquino, J. A.; Ringe, D.; Petsko, G. A. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability Biochemistry 2009, 48, 4816-4827
51. Matulis, D.; Kranz, J. K.; Salemme, F. R.; Todd, M. J. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor Biochemistry 2005, 44, 5258-5266 (Pubitemid 40471238)
52. Basu, A.; Glew, R. H. Characterization of the activation of rat liver beta-glucosidase sialosylgangliotetraosylceramide J. Biol. Chem. 1985, 260, 13067-13073 (Pubitemid 16209777)
53. Choy, F. Y; Woo, M.; Potier, M. In situ radiation-inactivation size of fibroblast membrane-bound acid beta-glucosidase in Gaucher type 1, type 2 and type 3 disease Biochim. Biophys. Acta 1986, 870, 76-81 (Pubitemid 16073488)
54. Hodanová, K.; Melková, Z.; Horowitz, M.; Hrebízek, M. Transient expression of wild-type and mutant glucocerebrosidases in hybrid vaccinia expression system Eur. J. Hum. Genet. 2003, 11, 369-374
55. Slavik, J. Anilinonaphthalene sulfonate as a probe of membrane composition and function Biochim. Biophys. Acta 1982, 694, 1-25
56. Apiyo, D.; Guidry, J.; Wittung-Stafshede, P. No cofactor effect on equilibrium unfolding of Desulfovibrio desulfuricans flavodoxin Biochim. Biophys. Acta 2000, 1479, 214-224 (Pubitemid 30345639)
57. Permyakov, S. E.; Oberg, K. A.; Cherskaya, A. M.; Shavlovsky, M. M.; Permyakov, E. A.; Uversky, V. N. Human alpha-fetoprotein as a Zn(2+)-binding protein. Tight cation binding is not accompanied by global changes in protein structure and stability Biochim. Biophys. Acta 2002, 1586, 1-10 (Pubitemid 34066611)
58. Permyakov, S. E.; Cherskaya, A. M.; Wasserman, L. A.; Khokhlova, T. I.; Senin, I. I.; Zargarov, A. A. Recoverin is a zinc-binding protein J. Proteome Res. 2003, 2, 51-57 (Pubitemid 36207190)
59. Cimmperman, P.; Baranauskiene, L.; Jachimoviciute, S.; Jachno, J.; Torresan, J.; Michailoviene, V. A quantitative model of thermal stabilization and destabilization of proteins by ligands Biophys. J. 2008, 95, 3222-3231
60. Abian, O.; Vega, S.; Neira, J. L.; Velazquez-Campoy, A. Conformational stability of hepatitis C virus NS3 protease Biophys. J. 2010, 99, 3811-3820
61. Sun, Y.; Ran, H.; Liou, B.; Quinn, B.; Zamzow, M.; Zhang, W. Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse PLoS One 2011, 6, e19037
62. Zechel, D. L.; Boraston, A. B.; Gloster, T.; Boraston, C. M.; MacDonald, J M.; Tilbrook, M. G. Iminosugar glycosidase inhibitors: Structural and thermodynamic dissection of the binding of isofagomine and 1-deoxynojirimycin to beta-glucosidases J. Am. Chem. Soc. 2003, 125, 14313-14323 (Pubitemid 37452370)
63. Porto, C; Cardone, M.; Fontana, F.; Rossi, B.; Tuzzi, M. R.; Tarallo, A. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts Mol. Ther. 2009, 17, 964-971
64. Schmitz, M.; Alfalah, M.; Aerts, J. M.; Naim, H. Y.; Zimmer, K. P. Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease Int. J. Biochem. Cell Biol. 2005, 37, 2310-2320 (Pubitemid 41207403)
65. Maas, C.; Hermeling, S.; Bouma, B.; Jiskoot, W.; Gebbink, M. F. A role for protein misfolding in immunogenicity of biopharmaceuticals J. Biol. Chem. 2007, 282, 2229-2236 (Pubitemid 47076754)